ESLA
Estrella Immunopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.65
+0.83%Aug 11, 2026, 12:00 UTC
Estrella Immunopharma activated University Hospitals Cleveland Medical Center as the fourth clinical site for its Phase I/II STARLIGHT-1 trial of EB103 in B-cell non-Hodgkin's lymphoma.
Source:Aug 3, 2026, 12:00 UTC
Estrella Immunopharma activated Oregon Health & Science University as the third clinical site for its Phase I/II STARLIGHT-1 trial of EB103 in B-cell non-Hodgkin's lymphoma.
Source:Jul 24, 2026, 12:00 UTC
Estrella Immunopharma dosed the first patient in the dose-expansion phase of its STARLIGHT-1 clinical trial for EB103 therapy in advanced B-cell non-Hodgkin's lymphoma.
Source: